



# Market Announcement

3 October 2024

---

## Immuron Limited (ASX: IMC) – Trading Halt

### Description

The securities of Immuron Limited ('IMC') will be placed in trading halt at the request of IMC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 7 October 2024 or when the announcement is released to the market.

### Issued by

ASX Compliance

For personal use only

3 October 2024

Melissa Kostopoulos  
Compliance Adviser, Listings Compliance  
ASX Compliance Pty Ltd  
Level 50, South Tower, Rialto  
525 Collins St Melbourne VIC 3000

By email: TradingHaltsMelbourne@asx.com.au  
ListingsComplianceMelbourne@asx.com.au

Dear Melissa

**Request for Trading Halt - Immuron Limited**

In accordance with ASX Listing Rule 17.1, Immuron Limited (ASX: IMC; NASDAQ: IMRN) (the Company) requests an immediate trading halt in respect of its securities. This trading halt is requested to allow Immuron to analyse and interpret CampETEC Hyperimmune Bovine Colostrum (HBC) ([clinicaltrials.gov/study/NCT06122870](https://clinicaltrials.gov/study/NCT06122870)) clinical trial data prior to making an announcement.

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on 7 October 2024, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt.

Please contact me if you require any further information.

Yours sincerely

Phillip Hains  
Company Secretary



For personal use only